Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12509506 | 0.96 | CYP2C9 (0.60) | CYP2C9KCNH2CYP3A4NR1I2ABCB11 | |
| SCHEMBL14849100 | 0.94 | CYP2C9 (0.55) | CYP2C9KCNH2CYP3A4NR1I2ABCB11 | |
| SCHEMBL12509501 | 0.91 | CYP2C9 (0.55) | CYP2C9KCNH2CYP3A4NR1I2ABCB11 | |
| SCHEMBL12509605 | 0.91 | CYP2C9 (0.55) | CYP2C9KCNH2CYP3A4NR1I2ABCB11 | |
| SCHEMBL15987157 | 0.91 | CYP2C9 (0.60) | CYP2C9KCNH2CYP3A4NR1I2ABCB11 | |
| SCHEMBL12509712 | 0.91 | CYP2C9 (0.56) | CYP2C9KCNH2CYP3A4NR1I2ABCB11 | |
| SCHEMBL12509683 | 0.90 | CYP2C9 (0.55) | CYP2C9KCNH2CYP3A4NR1I2ABCB11 | |
| SCHEMBL12509710 | 0.90 | CYP2C9 (0.55) | CYP2C9KCNH2CYP3A4 | |
| SCHEMBL15987115 | 0.90 | CYP3A4 (0.62) | CYP2C9KCNH2CYP3A4NR1I2ABCB11 | |
| SCHEMBL14841531 | 0.90 | CYP2C9 (0.55) | CYP2C9KCNH2CYP3A4NR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243257-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | disclosed |
| US-20130157997-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130157997-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-20 | — | — | US | disclosed |
| US-8354419-B2 | Benzimidazole analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-15 | — | — | US | disclosed |
| US-20110172238-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243257-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | BRI3BP, BLVRB, BRIX1 | CYP2C9 691/4885KCNH2 1322/4885CYP3A4 325/4885 |
| US-20110172238-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | BRI3BP, BLVRB, BRIX1 | CYP2C9 691/4885KCNH2 1322/4885CYP3A4 325/4885 |
| US-20130157997-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | BRI3BP, BLVRB, BRIX1 | CYP2C9 691/4885KCNH2 1322/4885CYP3A4 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.